Natco Pharma Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/yv4lc0nrlwy4j3j8gxt1hjn4.pdf

Key Takeaways


The Revlimid Bridge & Replacement Pipeline

Rajeev Nannapaneni: "I think it's not the lack of ideas. It's only about execution. I was just saying, right, if we pull off another 3 ideas in the next 2 years, we have done a great job."

Base Business & RoW Expansion

Rajeev Nannapaneni: "Emerging Markets are very interesting, They are very consistent. They are a lot like domestic. I mean, there you have local brands and you have a sustainable business. You have a distribution arm, which is consistent and large and gives you stability in earnings."

Crop Sciences: A Reset, Not a Write-Off

Rajeev Nannapaneni: "I think we have done well with the CTPR combination. Pheromone has not taken off as well as we thought. I think it's a lot of appreciation for the product, but I think the pricing has been on the higher side because of the cost of goods being high."

Margins, Costs & Capital Allocation

Rajeev Nannapaneni: "Say less, then you do more, people are happy with you. If you say more and you do less, everybody is unhappy with you. So, I think that's my way of looking at it."

Early-Stage Bets & Regulatory Overhang

Rajeev Nannapaneni: "Nothing is easy... I think we have proved ourselves consistently over the last decade that we can deliver these complex generics. And we have good execution capabilities. I think there's no doubt in that. We have a knack for finding these niches."

Guidance & Commitments

CommitmentSpecificsTimeline
Profit growthGreater than 20% growth for FY25FY25
Top-line growthMore than 15% to 20% growthFY25
Earnings growthAbout 20% comfortably, based on certain price erosion assumptionsFY25
Domestic formulation growth14% to 15% growth from Rs. 386 crore FY24 baseFY25
Crop Sciences targetTriple the business to Rs. 300 croresNext 3 years
CAPEXRs. 300-350 crores per year for maintenance and expansion at existing sitesOngoing
Revlimid profit share with TevaContinue on pretty much the same terms beyond Jan '26 settlement datePost-January 2026
First-to-file execution targetAchieve 2-3 first-to-files with limited competition; even 1-1.5 is a great jobNext 2 years
RoW acquisitionHoping to find a large acquisition to strengthen base businessNext couple of years
BuybackConsider if unable to close a large acquisitionDecision during FY25

Key Metrics

MetricQ4 FY24
Consolidated total revenue (FY24)₹4,126.9 cr, +47% YoY vs ₹2,811.7 cr
Consolidated net profit (FY24)₹1,388.3 cr, +94% YoY vs ₹715.3 cr
Q4 PAT₹380 cr, after exceptional cost of ₹90 cr
One-time charge (domestic)₹90 cr, includes ₹35 cr domestic business model change and agro inventory hit
Domestic business annual sales (FY24)~₹386 cr, growing 8–10%
Base business PAT~₹350–400 cr (per management estimate)
Cash and investable liquid assets₹2,004 cr as of May 26, 2024; net cash position
Debt₹116 cr, comprising ₹40 cr EPC credit and ₹76 cr foreign discounting
Other income (Q4)₹42 cr, of which ~₹30 cr from interest on deposits
Brazil exports (annual)$25–26 mn, direct plus subsidiary exports
Canada subsidiary profit~CAD 4 cr
Agri business revenue (FY24)~₹110–120 cr, fell short of ₹140–150 cr target by ₹25–30 cr
Agri business target (3-year)₹300 cr, internal target to triple
Annual CAPEX₹300–350 cr, maintenance and capacity expansion at existing sites
Employee count~5,000 excluding contractors, ~5,700–5,800 including contractors
Operating margin (FY24)43%, up from 33% in FY23 and 29% in FY21
FY25 revenue growth guidance>15–20%
FY25 earnings growth guidance~20%